Next results · Q3 2026Projected
Nov 12, after the close
Thu, Nov 12, 2026in 11 days
Projected from its last 8 releases. The company has not named the day yet.
- Quarter
- Q3 2026 · Ended Sep 30, 2026
- 10-Q window
- Nov 3 – 16
Read against Q3 2025
The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.
- Revenue
- —
- Revenue, change from a year earlier: Q4 2024 n/m, Q3 2024 +854.9%, Q2 2024 n/m, Q1 2024 n/m
- Net income
- -$1.24M
- Net income, change from a year earlier: Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m, Q3 2025 n/m
- EPS
- -$0.15
- EPS, change from a year earlier: Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m, Q2 2025 n/m
Results day
Typical moveA typical move of 3.1% either way
Up after 2 of 12, down after 10.
The stock’s move from the last close before each release to the first close after it, over the last 12 releases. Largest: +66.6% after Q1 2026.
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
When it reports
- Usual day
- Varies
- Session
- after the close
- After quarter end
- 30 to 77 days
- 10-Q filed
- 37 to 44 days
- over its last 8
- 10-K filed
- 71 to 81 days
- over its last 8
Based on 8 prior 10-Q filings.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR